07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

AGS67E: Phase I data

Data from 30 patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) in an open-label, dose-escalation, North American Phase I trial showed that IV AGS67E every 3 weeks without growth factor...